SCNI - InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month's Europe Dermatology Drug Development Summit
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, will be featured at this month’s annual Dermatology Drug Development Summit Europe. During the three-day gathering, SCNI chief science officer Dr. Tamar Ben-Yedidia will discuss the company’s NanoAbs as a local treatment for plaque psoriasis; Ben-Yedidia will be joined by Professor Michael Schön, director of the University Medical Center Göttingen's Department of Dermatology, Venereology & Allergology. The summit is scheduled for April 16–18, 2024, in Berlin; SCNI’s presentation is slated to begin at 11 a.m. CET on April 17. In addition, Scinai CEO Amir Reichman will participate in a panel discussion titled "Route of Administration & Formulations: How Can We Improve?” That panel is also scheduled for April 17, and will begin at 2:45 p.m. CET. In their presentation, Ben-Yedidia and Schön will discuss the unmet need in the mild-to-moderate plaque psoriasis space as well as the clinical potential of a local therapy based on anti-IL-17A/F NanoAbs; the presentation will also provide results from ex-vivo 3D biologic human skin models suggesting the therapeutic potential of Scinai's anti-IL-17A/F NanoAb and will include the use of a human xenograft model to evaluate anti-IL-17 NanoAbs as a local treatment for plaque psoriasis. The Dermatology Drug Development summit is designed to gather key opinion leaders and innovators in the dermatology field for a “pivotal platform aligning with rapid advancements and emerging needs across inflammatory skin disease treatments.”
To view the full press release, visit https://ibn.fm/MwjiV
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early-stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN